{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T21:42:17Z","timestamp":1790890937883,"version":"4.1.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"University of Thessaly Central Library"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Pediatric systemic lupus erythematosus (SLE) is associated with high disease severity and significantly higher morbidity and mortality compared to adult-onset SLE, making it a particularly challenging condition to manage. Chimeric antigen receptor (CAR) T-cell therapy holds significant promise for improving outcomes in refractory pediatric SLE. However, the use of CAR T-cell therapy in pediatric patients presents unique challenges, including difficulty in collecting sufficient T cells. Pediatric patients may experience distinct side effects, such as age-specific toxicities or more pronounced neurotoxic events, requiring tailored monitoring and management. Additionally, the psychological impact on children and their families, facing potentially life-threatening treatment protocols, must be carefully addressed. To date, only four children with SLE have been treated with CAR T cells, highlighting the early stage of research in this area. The clinical outcomes provide hope that CAR T-cell therapy could offer a breakthrough in treating pediatric SLE; however, main limitations remain the small number of patients and the relatively short follow-up. More data are needed to fully assess the safety, efficacy, and long-term outcomes in this vulnerable population.\n                    <jats:table-wrap>\n                      <jats:table>\n                        <jats:tbody>\n                          <jats:tr>\n                            <jats:td colspan=\"2\">\n                              Key Points\u2022\u00a0\n                              <jats:italic>Pediatric SLE is characterized by more severe manifestations, higher morbidity, and increased mortality compared to adult-onset SLE.<\/jats:italic>\n                              \u2022\u00a0\n                              <jats:italic>CAR T-cell therapy shows promise as a potential treatment for refractory pediatric SLE aiming ideally towards long-term, drug-free remission.<\/jats:italic>\n                              \u2022\u00a0\n                              <jats:italic>CAR T-cell therapy in pediatric SLE presents unique challenges, including age-related toxicities, technical difficulties, and ethical considerations.<\/jats:italic>\n                              \u2022\u00a0\n                              <jats:italic>To date, results are available from only a handful of children with SLE treated with CAR T cells. Expected advancements in CAR T-cell technology, along with data from ongoing clinical trials involving children with SLE, will determine the pace and extent of CAR T-cell therapy application in pediatric SLE.<\/jats:italic>\n                            <\/jats:td>\n                          <\/jats:tr>\n                        <\/jats:tbody>\n                      <\/jats:table>\n                    <\/jats:table-wrap>\n                  <\/jats:p>","DOI":"10.1007\/s10067-025-07550-5","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T19:23:04Z","timestamp":1752261784000},"page":"657-667","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["CAR T cells in pediatric systemic lupus erythematosus"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2604-5090","authenticated-orcid":false,"given":"Theodora","family":"Simopoulou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4775-0410","authenticated-orcid":false,"given":"Athanasios","family":"Gkoutzourelas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4174-6576","authenticated-orcid":false,"given":"Christina G.","family":"Katsiari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"6","key":"7550_CR1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/s41590-020-0677-6","volume":"21","author":"GC Tsokos","year":"2020","unstructured":"Tsokos GC (2020) Autoimmunity and organ damage in systemic lupus erythematosus. Nat Immunol 21(6):605\u2013614. https:\/\/doi.org\/10.1038\/s41590-020-0677-6","journal-title":"Nat Immunol"},{"issue":"6","key":"7550_CR2","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1542\/pir.2023-006011","volume":"45","author":"A Sura","year":"2024","unstructured":"Sura A, Failing C, Co DO, Syverson G (2024) Childhood-onset systemic lupus erythematosus. Pediatr Rev 45(6):316\u2013328. https:\/\/doi.org\/10.1542\/pir.2023-006011","journal-title":"Pediatr Rev"},{"issue":"8","key":"7550_CR3","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1038\/s41590-024-01898-7","volume":"25","author":"GC Tsokos","year":"2024","unstructured":"Tsokos GC (2024) The immunology of systemic lupus erythematosus. Nat Immunol 25(8):1332\u20131343. https:\/\/doi.org\/10.1038\/s41590-024-01898-7","journal-title":"Nat Immunol"},{"key":"7550_CR4","doi-asserted-by":"publisher","first-page":"110222","DOI":"10.1016\/j.clim.2024.110222","volume":"263","author":"SNC Liossis","year":"2024","unstructured":"Liossis SNC (2024) The abnormal signaling of the B cell receptor and co-receptors of lupus B cells. Clin Immunol Orlando Fla 263:110222. https:\/\/doi.org\/10.1016\/j.clim.2024.110222","journal-title":"Clin Immunol Orlando Fla"},{"issue":"6","key":"7550_CR5","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.semarthrit.2008.11.002","volume":"39","author":"CG Katsiari","year":"2010","unstructured":"Katsiari CG, Liossis SNC, Sfikakis PP (2010) \u2018The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: a reappraisal. Semin Arthritis Rheum 39(6):491\u2013503. https:\/\/doi.org\/10.1016\/j.semarthrit.2008.11.002","journal-title":"Semin Arthritis Rheum"},{"key":"7550_CR6","doi-asserted-by":"publisher","first-page":"214","DOI":"10.3389\/fimmu.2019.00214","volume":"10","author":"MGL Wilkinson","year":"2019","unstructured":"Wilkinson MGL, Rosser EC (2019) B cells as a therapeutic target in paediatric rheumatic disease. Front Immunol 10:214. https:\/\/doi.org\/10.3389\/fimmu.2019.00214","journal-title":"Front Immunol"},{"key":"7550_CR7","doi-asserted-by":"publisher","first-page":"152479","DOI":"10.1016\/j.semarthrit.2024.152479","volume":"67","author":"R Ohno","year":"2024","unstructured":"Ohno R, Nakamura A (2024) Advancing autoimmune rheumatic disease treatment: CAR-T cell therapies - evidence, safety, and future directions. Semin Arthritis Rheum 67:152479. https:\/\/doi.org\/10.1016\/j.semarthrit.2024.152479","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"7550_CR8","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1002\/acr.21757","volume":"64","author":"CA Silva","year":"2012","unstructured":"Silva CA, Avcin T, Brunner HI (2012) Taxonomy for systemic lupus erythematosus with onset before adulthood. Arthritis Care Res 64(12):1787\u20131793. https:\/\/doi.org\/10.1002\/acr.21757","journal-title":"Arthritis Care Res"},{"issue":"8","key":"7550_CR9","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.1002\/art.34473","volume":"64","author":"M Petri","year":"2012","unstructured":"Petri M et al (2012) Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64(8):2677\u20132686. https:\/\/doi.org\/10.1002\/art.34473","journal-title":"Arthritis Rheum"},{"issue":"9","key":"7550_CR10","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1002\/art.40930","volume":"71","author":"M Aringer","year":"2019","unstructured":"Aringer M et al (2019) 2019 European League Against Rheumatism\/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis Rheumatol 71(9):1400\u20131412. https:\/\/doi.org\/10.1002\/art.40930","journal-title":"Arthritis Rheumatol"},{"key":"7550_CR11","doi-asserted-by":"publisher","first-page":"1128754","DOI":"10.3389\/fimmu.2023.1128754","volume":"14","author":"L Pan","year":"2023","unstructured":"Pan L, Liu J, Liu C, Guo L, Punaro M, Yang S (2023) Childhood-onset systemic lupus erythematosus: characteristics and the prospect of glucocorticoid pulse therapy. Front Immunol 14:1128754. https:\/\/doi.org\/10.3389\/fimmu.2023.1128754","journal-title":"Front Immunol"},{"issue":"6","key":"7550_CR12","doi-asserted-by":"publisher","first-page":"1377","DOI":"10.1007\/s00467-020-04686-1","volume":"36","author":"L Oni","year":"2021","unstructured":"Oni L, Wright RD, Marks S, Beresford MW, Tullus K (2021) Kidney outcomes for children with lupus nephritis. Pediatr Nephrol Berl Ger 36(6):1377\u20131385. https:\/\/doi.org\/10.1007\/s00467-020-04686-1","journal-title":"Pediatr Nephrol Berl Ger"},{"key":"7550_CR13","doi-asserted-by":"publisher","unstructured":"Mauro A, Giani T, Di Mari C, Sandini M, Talenti A, Ansuini V, Biondi L, Di Nardo G, Bernardo L. (2023) Gastrointestinal involvement in children with systemic lupus erythematosus. Child Basel Switz 10(2):309. https:\/\/doi.org\/10.3390\/children10020309.","DOI":"10.3390\/children10020309"},{"issue":"8","key":"7550_CR14","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/S2352-4642(22)00157-2","volume":"6","author":"S Appenzeller","year":"2022","unstructured":"Appenzeller S, Pereira DR, Julio PR, Reis F, Rittner L, Marini R (2022) Neuropsychiatric manifestations in childhood-onset systemic lupus erythematosus. Lancet Child Adolesc Health 6(8):571\u2013581. https:\/\/doi.org\/10.1016\/S2352-4642(22)00157-2","journal-title":"Lancet Child Adolesc Health"},{"key":"7550_CR15","doi-asserted-by":"publisher","first-page":"108907","DOI":"10.1016\/j.clim.2021.108907","volume":"234","author":"T Alexander","year":"2022","unstructured":"Alexander T, Hedrich CM (2022) Systemic lupus erythematosus \u2013 are children miniature adults?\u2019. Clin Immunol 234:108907. https:\/\/doi.org\/10.1016\/j.clim.2021.108907","journal-title":"Clin Immunol"},{"issue":"4","key":"7550_CR16","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1586\/eci.09.29","volume":"5","author":"ED Papadimitraki","year":"2009","unstructured":"Papadimitraki ED, Isenberg DA (2009) Childhood- and adult-onset lupus: an update of similarities and differences. Expert Rev Clin Immunol 5(4):391\u2013403. https:\/\/doi.org\/10.1586\/eci.09.29","journal-title":"Expert Rev Clin Immunol"},{"key":"7550_CR17","doi-asserted-by":"publisher","first-page":"108898","DOI":"10.1016\/j.clim.2021.108898","volume":"234","author":"H Lythgoe","year":"2022","unstructured":"Lythgoe H, Lj M, Hedrich CM, Aringer M (2022) Classification of systemic lupus erythematosus in children and adults. Clin Immunol 234:108898. https:\/\/doi.org\/10.1016\/j.clim.2021.108898","journal-title":"Clin Immunol"},{"issue":"7909","key":"7550_CR18","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41586-022-04642-z","volume":"605","author":"GJ Brown","year":"2022","unstructured":"Brown GJ et al (2022) TLR7 gain-of-function genetic variation causes human lupus. Nature 605(7909):349\u2013356. https:\/\/doi.org\/10.1038\/s41586-022-04642-z","journal-title":"Nature"},{"issue":"3","key":"7550_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11926-021-00985-0","volume":"23","author":"A Charras","year":"2021","unstructured":"Charras A, Smith E, Hedrich CM (2021) Systemic lupus erythematosus in children and young people. Curr Rheumatol Rep 23(3):20. https:\/\/doi.org\/10.1007\/s11926-021-00985-0","journal-title":"Curr Rheumatol Rep"},{"issue":"37","key":"7550_CR20","doi-asserted-by":"publisher","first-page":"e8086","DOI":"10.1097\/MD.0000000000008086","volume":"96","author":"PK Bundhun","year":"2017","unstructured":"Bundhun PK, Kumari A, Huang F (2017) Differences in clinical features observed between childhood-onset versus adult-onset systemic lupus erythematosus: a systematic review and meta-analysis. Medicine (Baltimore) 96(37):e8086. https:\/\/doi.org\/10.1097\/MD.0000000000008086","journal-title":"Medicine (Baltimore)"},{"issue":"1","key":"7550_CR21","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1159\/000518321","volume":"183","author":"X Huang","year":"2022","unstructured":"Huang X, Jia N, Xiao F, Sun C, Zhu J, Lai J, Cui X (2022) Differences in the clinical manifestations and mortality of systemic lupus erythematosus onset in children and adults: a systematic review and meta-analysis. Int Arch Allergy Immunol 183(1):116\u2013126. https:\/\/doi.org\/10.1159\/000518321","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"7550_CR22","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1002\/art.23204","volume":"58","author":"HI Brunner","year":"2008","unstructured":"Brunner HI, Gladman DD, Iba\u00f1ez D, Urowitz MD, Silverman ED (2008) Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum 58(2):556\u2013562. https:\/\/doi.org\/10.1002\/art.23204","journal-title":"Arthritis Rheum"},{"issue":"14","key":"7550_CR23","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1177\/0961203316644333","volume":"25","author":"Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW, Isenberg DA; UK JSLE Study Group","year":"2016","unstructured":"Ambrose N, Morgan TA, Galloway J, Ionnoau Y, Beresford MW, Isenberg DA; UK JSLE Study Group (2016) Differences in disease phenotype and severity in SLE across age groups. Lupus 25(14):1542\u20131550. https:\/\/doi.org\/10.1177\/0961203316644333","journal-title":"Lupus"},{"issue":"4","key":"7550_CR24","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1177\/0961203307087875","volume":"17","author":"LB Tucker","year":"2008","unstructured":"Tucker LB, Uribe AG, Fern\u00e1ndez M, Vil\u00e1 LM, McGwin G, Apte M, Fessler BJ, Bastian HM, Reveille JD, Alarc\u00f3n GS (2008) Adolescent onset of lupus results in more aggressive disease and worse outcomes: results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus 17(4):314\u2013322. https:\/\/doi.org\/10.1177\/0961203307087875","journal-title":"Lupus"},{"issue":"1","key":"7550_CR25","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1002\/art.24091","volume":"61","author":"AO Hersh","year":"2009","unstructured":"Hersh AO, von Scheven E, Yazdany J, Panopalis P, Trupin L, Julian L, Katz P, Criswell LA, Yelin E (2009) Differences in long-term disease activity and treatment of adult patients with childhood- and adult-onset systemic lupus erythematosus. Arthritis Rheum 61(1):13\u201320. https:\/\/doi.org\/10.1002\/art.24091","journal-title":"Arthritis Rheum"},{"issue":"1","key":"7550_CR26","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.rdc.2009.12.012","volume":"36","author":"R Mina","year":"2010","unstructured":"Mina R, Brunner HI (2010) Pediatric lupus\u2014are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin N Am 36(1):53\u201380. https:\/\/doi.org\/10.1016\/j.rdc.2009.12.012","journal-title":"Rheum Dis Clin N Am"},{"issue":"8","key":"7550_CR27","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1093\/rheumatology\/kead519","volume":"63","author":"SR Moe","year":"2024","unstructured":"Moe SR, Haukeland H, Brunborg C, Botea A, Damjanic N, Wivestad G\u00c5, \u00d8vre\u00e5s H, B\u00f8e T, Orre A, Garen T, Lilleby V, Provan SA, Molberg \u00d8, Lerang K (2024) Persisting mortality gap in systemic lupus erythematosus; a population-based study on juvenile- and adult-onset SLE in Norway 1999\u20132022. Rheumatol Oxf Engl 63(8):2109\u20132117. https:\/\/doi.org\/10.1093\/rheumatology\/kead519","journal-title":"Rheumatol Oxf Engl"},{"issue":"1","key":"7550_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1002\/jcph.2139","volume":"63","author":"SJ Balevic","year":"2023","unstructured":"Balevic SJ, Niu J, Chen J, Green D, McMahon A, Hornik CP, Schanberg LE, Glaser R, Gonzalez D, Burckart GJ (2023) Extrapolation of adult efficacy data to pediatric systemic lupus erythematosus: evaluating similarities in exposure-response. J Clin Pharmacol 63(1):105\u2013118. https:\/\/doi.org\/10.1002\/jcph.2139","journal-title":"J Clin Pharmacol"},{"issue":"11","key":"7550_CR29","doi-asserted-by":"publisher","first-page":"1788","DOI":"10.1136\/annrheumdis-2016-210960","volume":"76","author":"N Groot","year":"2017","unstructured":"Groot N et al (2017) European evidence-based recommendations for diagnosis and treatment of childhood-onset systemic lupus erythematosus: the SHARE initiative. Ann Rheum Dis 76(11):1788\u20131796. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210960","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"7550_CR30","doi-asserted-by":"publisher","first-page":"e000153","DOI":"10.1136\/lupus-2016-000153","volume":"3","author":"G Ruiz-Irastorza","year":"2016","unstructured":"Ruiz-Irastorza G et al (2016) First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. Lupus Sci Med 3(1):e000153. https:\/\/doi.org\/10.1136\/lupus-2016-000153","journal-title":"Lupus Sci Med"},{"issue":"8","key":"7550_CR31","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1016\/j.autrev.2017.05.017","volume":"16","author":"G Ruiz-Irastorza","year":"2017","unstructured":"Ruiz-Irastorza G et al (2017) Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: an observational comparative study of the Lupus-Cruces and lupus-Bordeaux cohorts. Autoimmun Rev 16(8):826\u2013832. https:\/\/doi.org\/10.1016\/j.autrev.2017.05.017","journal-title":"Autoimmun Rev"},{"issue":"4","key":"7550_CR32","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1002\/acr.23322","volume":"70","author":"I Ruiz-Arruza","year":"2018","unstructured":"Ruiz-Arruza I et al (2018) Restrictive use of oral glucocorticoids in systemic lupus erythematosus and prevention of damage without worsening long-term disease control: an observational study. Arthritis Care Res 70(4):582\u2013591. https:\/\/doi.org\/10.1002\/acr.23322","journal-title":"Arthritis Care Res"},{"issue":"9","key":"7550_CR33","doi-asserted-by":"publisher","first-page":"102359","DOI":"10.1016\/j.autrev.2019.102359","volume":"18","author":"G Ruiz-Irastorza","year":"2019","unstructured":"Ruiz-Irastorza G et al (2019) Prolonged remission in SLE is possible by using reduced doses of prednisone: an observational study from the Lupus-Cruces and Lupus-Bordeaux inception cohorts. Autoimmun Rev 18(9):102359. https:\/\/doi.org\/10.1016\/j.autrev.2019.102359","journal-title":"Autoimmun Rev"},{"issue":"3","key":"7550_CR34","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s10067-023-06833-z","volume":"43","author":"R Elshaer","year":"2024","unstructured":"Elshaer R, Jaber S, Odeh N, Arbili L, Al-Mayouf SM (2024) Safety and efficacy of biologics in childhood systemic lupus erythematosus: a critical systematic review. Clin Rheumatol 43(3):863\u2013877. https:\/\/doi.org\/10.1007\/s10067-023-06833-z","journal-title":"Clin Rheumatol"},{"key":"7550_CR35","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/j.critrevonc.2015.09.001","volume":"97","author":"N Seyfizadeh","year":"2016","unstructured":"Seyfizadeh N, Seyfizadeh N, Hasenkamp J, Huerta-Yepez S (2016) A molecular perspective on rituximab: a monoclonal antibody for B cell non Hodgkin lymphoma and other affections. Crit Rev Oncol Hematol 97:275\u2013290. https:\/\/doi.org\/10.1016\/j.critrevonc.2015.09.001>","journal-title":"Crit Rev Oncol Hematol"},{"issue":"10","key":"7550_CR36","doi-asserted-by":"publisher","first-page":"1340","DOI":"10.1136\/annrheumdis-2020-217101","volume":"79","author":"HI Brunner","year":"2020","unstructured":"Brunner HI et al (2020) Safety and efficacy of intravenous belimumab in children with systemic lupus erythematosus: results from a randomised, placebo-controlled trial. Ann Rheum Dis 79(10):1340\u20131348. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217101","journal-title":"Ann Rheum Dis"},{"key":"7550_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/acr.25482","author":"M Shishov","year":"2024","unstructured":"Shishov M et al (2024) 25 years of biologics for the treatment of pediatric rheumatic disease: advances in prognosis and ongoing challenges. Arthritis Care Res. https:\/\/doi.org\/10.1002\/acr.25482","journal-title":"Arthritis Care Res"},{"key":"7550_CR38","doi-asserted-by":"publisher","unstructured":"Cochrane RW, Robino RA, Ferreira LMR (2025) Generation of human chimeric antigen receptor regulatory T cells. J Vis Exp JoVE 215. https:\/\/doi.org\/10.3791\/67200.","DOI":"10.3791\/67200"},{"key":"7550_CR39","doi-asserted-by":"publisher","first-page":"103369","DOI":"10.1016\/j.jaut.2025.103369","volume":"151","author":"V Uppin","year":"2025","unstructured":"Uppin V, Gibbons H, Troje M, Feinberg D, Webber BR, Moriarity BS, Parameswaran R (2025) CAR-T cell targeting three receptors on autoreactive B cells for systemic lupus erythematosus therapy. J Autoimmun 151:103369. https:\/\/doi.org\/10.1016\/j.jaut.2025.103369","journal-title":"J Autoimmun"},{"key":"7550_CR40","doi-asserted-by":"publisher","first-page":"1502712","DOI":"10.3389\/fimmu.2024.1502712","volume":"15","author":"C Rangel-Pel\u00e1ez","year":"2024","unstructured":"Rangel-Pel\u00e1ez C, Mart\u00ednez-Guti\u00e9rrez L, Trist\u00e1n-Manzano M, Callejas JL, Ortego-Centeno N, Mart\u00edn F, Mart\u00edn J (2024) CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases? Front Immunol 15:1502712. https:\/\/doi.org\/10.3389\/fimmu.2024.1502712","journal-title":"Front Immunol"},{"issue":"6","key":"7550_CR41","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41584-023-00968-8","volume":"19","author":"TH Finkel","year":"2023","unstructured":"Finkel TH, Radic M (2023) Chimeric receptors broaden the therapeutic landscape for autoimmune disease. Nat Rev Rheumatol 19(6):327\u2013328. https:\/\/doi.org\/10.1038\/s41584-023-00968-8","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"7550_CR42","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1136\/ard-2024-226142","volume":"84","author":"C Tur","year":"2025","unstructured":"Tur C et al (2025) CD19-CAR T-cell therapy induces deep tissue depletion of B cells. Ann Rheum Dis 84(1):106\u2013114. https:\/\/doi.org\/10.1136\/ard-2024-226142","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"7550_CR43","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood.2024025130","volume":"144","author":"T Siddiqi","year":"2024","unstructured":"Siddiqi T (2024) CARs vs bispecifics: the race is on! Blood 144(6):592\u2013593. https:\/\/doi.org\/10.1182\/blood.2024025130","journal-title":"Blood"},{"issue":"12","key":"7550_CR44","doi-asserted-by":"publisher","first-page":"3485","DOI":"10.3324\/haematol.2023.282875","volume":"108","author":"C Lacan","year":"2023","unstructured":"Lacan C et al (2023) CAR T-cell therapy for central nervous system lymphomas: blood and cerebrospinal fluid biology, and outcomes. Haematologica 108(12):3485\u20133490. https:\/\/doi.org\/10.3324\/haematol.2023.282875","journal-title":"Haematologica"},{"issue":"6","key":"7550_CR45","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell KM, Kochenderfer JN (2023) Long-term outcomes following CAR T cell therapy: what we know so far. Nat Rev Clin Oncol 20(6):359\u2013371. https:\/\/doi.org\/10.1038\/s41571-023-00754-1","journal-title":"Nat Rev Clin Oncol"},{"issue":"10","key":"7550_CR46","doi-asserted-by":"publisher","first-page":"2124","DOI":"10.1038\/s41591-022-02017-5","volume":"28","author":"A Mackensen","year":"2022","unstructured":"Mackensen A et al (2022) Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus. Nat Med 28(10):2124\u20132132. https:\/\/doi.org\/10.1038\/s41591-022-02017-5","journal-title":"Nat Med"},{"key":"7550_CR47","doi-asserted-by":"publisher","first-page":"101104","DOI":"10.1016\/j.omtm.2023.08.023","volume":"31","author":"D Nunez","year":"2023","unstructured":"Nunez D, Patel D, Volkov J, Wong S, Vorndran Z, M\u00fcller F, Aigner M, V\u00f6lkl S, Mackensen A, Schett G, Basu S (2023) Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy. Mol Ther Methods Clin Dev 31:101104. https:\/\/doi.org\/10.1016\/j.omtm.2023.08.023","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"7550_CR48","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1056\/NEJMc2107725","volume":"385","author":"D Mougiakakos","year":"2021","unstructured":"Mougiakakos D, Kr\u00f6nke G, V\u00f6lkl S, Kretschmann S, Aigner M, Kharboutli S, B\u00f6ltz S, Manger B, Mackensen A, Schett G (2021) CD19-targeted CAR T cells in refractory systemic lupus erythematosus. N Engl J Med 385(6):567\u2013569. https:\/\/doi.org\/10.1056\/NEJMc2107725","journal-title":"N Engl J Med"},{"key":"7550_CR49","doi-asserted-by":"publisher","unstructured":"M\u00fcller F et al (2024) CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up. N Engl J Med 390(8):687\u2013700. https:\/\/doi.org\/10.1056\/NEJMoa2308917.","DOI":"10.1056\/NEJMoa2308917"},{"issue":"10437","key":"7550_CR50","doi-asserted-by":"publisher","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","volume":"403","author":"T Krickau","year":"2024","unstructured":"Krickau T, Naumann-Bartsch N, Aigner M, Kharboutli S, Kretschmann S, Spoerl S, Vasova I, V\u00f6lkl S, Woelfle J, Mackensen A, Schett G, Metzler M, M\u00fcller F (2024) CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis. Lancet Lond Engl 403(10437):1627\u20131630. https:\/\/doi.org\/10.1016\/S0140-6736(24)00424-0","journal-title":"Lancet Lond Engl"},{"key":"7550_CR51","doi-asserted-by":"publisher","unstructured":"Marasco E et al (2024) Anti-CD19 CAR-T cell therapy for refractory childhood-onset systemic lupus erythematosus. Lupus Science & Medicine 11. https:\/\/doi.org\/10.1136\/lupus-2024-el.155","DOI":"10.1136\/lupus-2024-el.155"},{"issue":"1","key":"7550_CR52","doi-asserted-by":"publisher","first-page":"103692","DOI":"10.1016\/j.autrev.2024.103692","volume":"24","author":"X He","year":"2025","unstructured":"He X, Hu B, Zhang Y, Liu F, Li Q, Zheng C, Shen J, Yang Z, Wang J, Ma D, Qian C, Lu M, Mao J (2025) Treatment of two pediatric patients with refractory systemic lupus erythematosus using CD19-targeted CAR T-cells. Autoimmun Rev 24(1):103692. https:\/\/doi.org\/10.1016\/j.autrev.2024.103692","journal-title":"Autoimmun Rev"},{"issue":"5","key":"7550_CR53","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1056\/NEJMoa1709866","volume":"378","author":"SL Maude","year":"2018","unstructured":"Maude SL et al (2018) Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 378(5):439\u2013448. https:\/\/doi.org\/10.1056\/NEJMoa1709866","journal-title":"N Engl J Med"},{"issue":"3","key":"7550_CR54","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.annonc.2021.12.003","volume":"33","author":"PJ Hayden","year":"2021","unstructured":"Hayden PJ et al (2021) Management of adults and children receiving CAR T-cell therapy: 2021 best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE) and the European Haematology Association (EHA). Ann Oncol Off J Eur Soc Med Oncol 33(3):259\u2013275. https:\/\/doi.org\/10.1016\/j.annonc.2021.12.003","journal-title":"Ann Oncol Off J Eur Soc Med Oncol"},{"issue":"1","key":"7550_CR55","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","volume":"16","author":"KM Mahadeo","year":"2019","unstructured":"Mahadeo KM et al (2019) Management guidelines for paediatric patients receiving chimeric antigen receptor T cell therapy. Nat Rev Clin Oncol 16(1):45\u201363. https:\/\/doi.org\/10.1038\/s41571-018-0075-2","journal-title":"Nat Rev Clin Oncol"},{"issue":"7","key":"7550_CR56","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.3390\/biomedicines12071622","volume":"12","author":"P Marschollek","year":"2024","unstructured":"Marschollek P et al (2024) The kinetics of inflammation-related proteins and cytokines in children undergoing CAR-T cell therapy-are they biomarkers of therapy-related toxicities? Biomedicines 12(7):1622. https:\/\/doi.org\/10.3390\/biomedicines12071622","journal-title":"Biomedicines"},{"issue":"2","key":"7550_CR57","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","volume":"22","author":"EC Morris","year":"2022","unstructured":"Morris EC, Neelapu SS, Giavridis T, Sadelain M (2022) Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat Rev Immunol 22(2):85\u201396. https:\/\/doi.org\/10.1038\/s41577-021-00547-6","journal-title":"Nat Rev Immunol"},{"key":"7550_CR58","doi-asserted-by":"publisher","first-page":"1144414","DOI":"10.3389\/fneur.2023.1144414","volume":"14","author":"R Velasco","year":"2023","unstructured":"Velasco R, Mussetti A, Villagr\u00e1n-Garc\u00eda M, Sureda A (2023) CAR T-cell-associated neurotoxicity in central nervous system hematologic disease: Is it still a concern? Front Neurol 14:1144414. https:\/\/doi.org\/10.3389\/fneur.2023.1144414","journal-title":"Front Neurol"},{"key":"7550_CR59","doi-asserted-by":"publisher","first-page":"634445","DOI":"10.3389\/fonc.2021.634445","volume":"11","author":"BD Brown","year":"2021","unstructured":"Brown BD, Tambaro FP, Kohorst M, Chi L, Mahadeo KM, Tewari P, Petropoulos D, Slopis JM, Sadighi Z, Khazal S (2021) Immune effector cell associated neurotoxicity (ICANS) in pediatric and young adult patients following chimeric antigen receptor (CAR) T-cell therapy: can we optimize early diagnosis? Front Oncol 11:634445. https:\/\/doi.org\/10.3389\/fonc.2021.634445","journal-title":"Front Oncol"},{"issue":"4","key":"7550_CR60","doi-asserted-by":"publisher","first-page":"e279","DOI":"10.1097\/HS9.0000000000000279","volume":"3","author":"AM DiNofia","year":"2019","unstructured":"DiNofia AM, Maude SL (2019) Chimeric antigen receptor T-cell therapy clinical results in pediatric and young adult B-ALL. HemaSphere 3(4):e279. https:\/\/doi.org\/10.1097\/HS9.0000000000000279","journal-title":"HemaSphere"},{"issue":"3","key":"7550_CR61","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1097\/CCM.0b013e3182a66b76","volume":"42","author":"C Traube","year":"2014","unstructured":"Traube C, Silver G, Kearney J, Patel A, Atkinson TM, Yoon MJ, Halpert S, Augenstein J, Sickles LE, Li C, Greenwald B (2014) Cornell Assessment of Pediatric Delirium: a valid, rapid, observational tool for screening delirium in the PICU*. Crit Care Med 42(3):656\u2013663. https:\/\/doi.org\/10.1097\/CCM.0b013e3182a66b76","journal-title":"Crit Care Med"},{"issue":"20","key":"7550_CR62","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1182\/blood.2022017604","volume":"141","author":"BD Santomasso","year":"2023","unstructured":"Santomasso BD, Gust J, Perna F (2023) How I treat unique and difficult-to-manage cases of CAR T-cell therapy-associated neurotoxicity. Blood 141(20):2443\u20132451. https:\/\/doi.org\/10.1182\/blood.2022017604","journal-title":"Blood"},{"issue":"2","key":"7550_CR63","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1177\/02692163221138880","volume":"37","author":"CL Stenson","year":"2023","unstructured":"Stenson CL, Vidrine J, Dewhurst F, Osborne W, Menne T, Stocker R (2023) A qualitative service evaluation of patient and caregiver experiences of CAR-T therapy: recommendations for service development and implications for palliative care teams. Palliat Med 37(2):215\u2013220. https:\/\/doi.org\/10.1177\/02692163221138880","journal-title":"Palliat Med"},{"issue":"6","key":"7550_CR64","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1093\/jpepsy\/jsw011","volume":"41","author":"DM Graef","year":"2016","unstructured":"Graef DM, Phipps S, Parris KR, Martin-Elbahesh K, Huang L, Zhang H, Crabtree VM (2016) Sleepiness, fatigue, behavioral functioning, and quality of life in survivors of childhood hematopoietic stem cell transplant. J Pediatr Psychol 41(6):600\u2013609. https:\/\/doi.org\/10.1093\/jpepsy\/jsw011","journal-title":"J Pediatr Psychol"},{"issue":"2","key":"7550_CR65","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1038\/bmt.2016.248","volume":"52","author":"SE Ghazikhanian","year":"2017","unstructured":"Ghazikhanian SE, Dorfman CS, Somers TJ, O\u2019Sullivan ML, Fisher HM, Edmond SN, Wren AA, Kelleher SA, Rowe Nichols KA, Chao N, Shelby RA (2017) Cognitive problems following hematopoietic stem cell transplant: relationships with sleep, depression and fatigue. Bone Marrow Transplant 52(2):279\u2013284. https:\/\/doi.org\/10.1038\/bmt.2016.248","journal-title":"Bone Marrow Transplant"},{"issue":"8047","key":"7550_CR66","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/s41586-024-08261-8","volume":"637","author":"D Steffin","year":"2025","unstructured":"Steffin D et al (2025) Interleukin-15-armoured GPC3 CAR T cells for patients with solid cancers. Nature 637(8047):940\u2013946. https:\/\/doi.org\/10.1038\/s41586-024-08261-8","journal-title":"Nature"},{"key":"7550_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2024.100739","volume":"24","author":"C Carcopino","year":"2024","unstructured":"Carcopino C, Erdogan E, Henrich M, Kobold S (2024) Armoring chimeric antigen receptor (CAR) T cells as micropharmacies for cancer therapy. Immuno-Oncol Technol 24:100739. https:\/\/doi.org\/10.1016\/j.iotech.2024.100739","journal-title":"Immuno-Oncol Technol"},{"issue":"1","key":"7550_CR68","doi-asserted-by":"publisher","first-page":"9917","DOI":"10.1038\/s41467-024-53996-7","volume":"15","author":"HB Park","year":"2024","unstructured":"Park HB et al (2024) Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters. Nat Commun 15(1):9917. https:\/\/doi.org\/10.1038\/s41467-024-53996-7","journal-title":"Nat Commun"},{"key":"7550_CR69","doi-asserted-by":"publisher","unstructured":"Mougiakakos D (2024) Allogeneic CAR T cells for autoimmune diseases: a glimpse into the future. Signal Transduct Target Ther 9(1):276. https:\/\/doi.org\/10.1038\/s41392-024-01998-8.","DOI":"10.1038\/s41392-024-01998-8"},{"issue":"18","key":"7550_CR70","doi-asserted-by":"publisher","first-page":"4890","DOI":"10.1016\/j.cell.2024.06.027","volume":"187","author":"X Wang","year":"2024","unstructured":"Wang X et al (2024) Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell 187(18):4890-4904.e9. https:\/\/doi.org\/10.1016\/j.cell.2024.06.027","journal-title":"Cell"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07550-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07550-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07550-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,30]],"date-time":"2026-01-30T09:01:49Z","timestamp":1769763709000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07550-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":70,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["7550"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07550-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,11]]},"assertion":[{"value":"12 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}